Lilly: Eli Lilly's lepodisiran cuts lipoprotein(a) by 93.9% in Phase II trial
The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor. The post Eli Lilly's lepodisiran cuts lipoprotein(a) by 93.9% in Phase II trial appeared first on Clinical Trials Arena.
Read full article »
Lilly is a Massachusetts-based pharmaceutical company that develops, produces and markets pharmaceutical products for healthcare professionals, patients and consumers.
Read more